Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026) Meeting Abstract
| Authors: | Erickson, B. K.; Enserro, D.; Lankes, H. A.; Dockery, L. E.; Ghamande, S. A.; Oliver, M. T.; Gressel, G. M.; Castellano, T.; Ratner, E.; Deery, A.; Bishop, E.; Bradford, L. S.; Pepin, J. T.; Burton, E.; Blank, S. V.; Santin, A.; Havrilesky, L. J.; Aghajanian, C.; Fader, A. N.; Powell, M. A. |
| Abstract Title: | Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026) |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557406279 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.TPS5641 |
| Notes: | Meeting Abstract: TPS5641 -- Source: Wos |
